Granted Patent
B2
US 12,371,466 · App. 17/115,565 · Granted Jul 29, 2025
Chimeric antigen receptor and methods of use thereof
Inventors:
Chia-Yung Wu (San Francisco, CA); James Onuffer (Alameda, CA); Wendell A. Lim (San Francisco, CA)
C07K14/705A61K35/17A61K40/11A61K40/31A61K40/4211A61K40/4255A61K47/6891C07K14/7051C07K14/70521C07K14/70575C07K14/70578C07K16/18C07K16/2803C07K16/2866C12N5/0636C12N9/14C12N9/90C12Y502/01008A61K2039/505A61K2239/23A61K2239/24A61K2239/31A61K2239/38C07K2317/622C07K2319/00C07K2319/03C07K2319/20C07K2319/33C07K2319/74C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
Claims (29)
1. One or more nucleic acids comprising a nucleotide sequence(s) encoding a heterodimeric chimeric antigen receptor (CAR) comprising:
a first polypeptide comprising a first member of a dimerization pair, a first transmembrane domain, and an intracellular signaling domain; and
a second polypeptide comprising a scFv or VHH domain that specifically binds to mesothelin, a second member of the dimerization pair, and a second transmembrane domain;
wherein:
the first and second members of the dimerization pair are intracellular,
a dimerizing agent dimerizes the heterodimeric CAR when the first and second polypeptides are expressed by a cell with the dimerizing agent bound between the dimerization pair members of the first and second polypeptides,
the first polypeptide does not comprise an antigen-binding domain and the second polypeptide does not comprise an intracellular signaling domain capable of inducing cell activation, and
activation of the cell by the formed heterodimeric CAR binding mesothelin or said antigen is increased as compared to activation of the cell in the absence of the dimerizing agent.
2. The one or more nucleic acids according to claim 1 , wherein the intracellular signaling domain is a CD3-zeta intracellular signaling domain or a ZAP-70 intracellular signaling domain.
3. The one or more nucleic acids according to claim 1 , wherein the intracellular signaling domain comprises an immunoreceptor tyrosine-based activation motif (ITAM).
4. The one or more nucleic acids according to claim 1 , wherein the first polypeptide, the second polypeptide or both comprise an intracellular costimulatory polypeptide.
5. The one or more nucleic acids according to claim 1 , wherein the intracellular costimulatory polypeptides are selected from the group consisting of: 4-1BB, CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.
6. The one or more nucleic acids according to claim 1 , wherein the first polypeptide comprises a first costimulatory polypeptide comprising an amino acid sequence and the second polypeptide comprises a second costimulatory polypeptide comprising an amino acid sequence that has at least 95% amino acid identity to the amino acid sequence of the first costimulatory polypeptide in the first polypeptide.
7. The one or more nucleic acids according to claim 1 , wherein the dimerizer agent is selected from the group consisting of: rapamycin, coumermycin, methotrexate, AP20187, abscisic acid, gibberellin and analogs thereof.
8. The one or more nucleic acids according to claim 1 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP-rapamycin associated protein (FRB);
b) a Gibberellic Acid Insensitive (GAI) protein and a gibberellin receptor (GID1) protein;
c) FKBP and calcineurin catalytic subunit A (CnA);
d) an abscisic acid receptor (PYL) protein and an abscissic acid insensitive (ABI) protein; and
e) FKBP and cyclophilin.
9. The one or more nucleic acids according to claim 1 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP;
b) gyrase B (GyrB) and GyrB;
c) dihydrofolate reductase (DHFR) and DHFR; and
d) DmrB and DmrB.
10. An isolated cell comprising the one or more nucleic acids according to claim 1 .
11. The isolated cell according to claim 10 , wherein the isolated cell is an immune cell.
12. The isolated cell according to claim 11 , wherein the immune cell is a lymphocyte or a NK cell.
13. The isolated cell according to claim 10 , wherein the cell is a human cell.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 8, 2020
From: WU, CHIA-YUNG; ONUFFER, JAMES; LIM, WENDELL A.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 054583/0488 →
Continuity (7)
References Cited (157)
US 5359046A
· Capon et al.
· 1994
[cited by applicant]
US 5712149A
· Roberts
· 1998
[cited by applicant]
US 5830462A
· Crabtree et al.
· 1998
[cited by applicant]
US 5834266A
· Crabtree et al.
· 1998
[cited by applicant]
US 5869337A
· Crabtree et al.
· 1999
[cited by applicant]
US 5871753A
· Crabtree et al.
· 1999
[cited by applicant]
US 5906936A
· Eshhar et al.
· 1999
[cited by applicant]
US 5912172A
· Eshhar et al.
· 1999
[cited by applicant]
US 6133456A
· Holt et al.
· 2000
[cited by applicant]
US 6150527A
· Holt et al.
· 2000
[cited by applicant]
US 6165787A
· Crabtree et al.
· 2000
[cited by applicant]
US 6410319B1
· Raubitschek et al.
· 2002
[cited by applicant]
US 6649595B2
· Clackson et al.
· 2003
[cited by applicant]
US 7404950B2
· Spencer et al.
· 2008
[cited by applicant]
US 7446179B2
· Jensen et al.
· 2008
[cited by applicant]
US 7446190B2
· Sadelain et al.
· 2008
[cited by applicant]
US 7741465B1
· Eshhar et al.
· 2010
[cited by applicant]
US 8106191B2
· Holt et al.
· 2012
[cited by applicant]
US 8399645B2
· Campana et al.
· 2013
[cited by applicant]
US 8492122B2
· Ostermeier
· 2013
[cited by applicant]
US 8771671B2
· Spencer et al.
· 2014
[cited by applicant]
US 8911993B2
· June et al.
· 2014
[cited by applicant]
US 8999949B2
· Spencer et al.
· 2015
[cited by applicant]
US 9587020B2
· Wu et al.
· 2017
[cited by applicant]
US 9745368B2
· Milone et al.
· 2017
[cited by applicant]
US 9821012B2
· Wu et al.
· 2017
[cited by applicant]
US 20030077249A1
· Bebbington et al.
· 2003
[cited by applicant]
US 20040038886A1
· Finney et al.
· 2004
[cited by applicant]
US 20050113564A1
· Campana et al.
· 2005
[cited by applicant]
US 20120277286A1
· Youle et al.
· 2012
[cited by applicant]
US 20130040836A1
· Himmler et al.
· 2013
[cited by applicant]
US 20130095097A1
· Blankenship et al.
· 2013
[cited by applicant]
US 20130195800A1
· Roeth et al.
· 2013
[cited by applicant]
US 20150368342A1
· Wu et al.
· 2015
[cited by applicant]
EP 481673
· 1992
[cited by applicant]
FR 2968013
· 2012
[cited by applicant]
WO WO2001032866
· 2001
[cited by applicant]
WO WO2002070559
· 2002
[cited by applicant]
WO WO2011119773A1
· 2011
[cited by applicant]
WO WO2012079000
· 2012
[cited by applicant]
WO WO2012099973A2
· 2012
[cited by applicant]
WO WO2014039523A1
· 2014
[cited by applicant]
WO WO2014127261
· 2014
[cited by applicant]
WO WO2015057852
· 2015
[cited by applicant]
WO WO2015090229
· 2015
[cited by applicant]
WO WO2015123527A1
· 2015
[cited by applicant]
WO WO2015142661
· 2015
[cited by applicant]
WO WO2015150771
· 2015
[cited by applicant]
WO WO2016055551
· 2016
[cited by applicant]
WO WO2017087723
· 2017
[cited by applicant]
WO WO2017120546
· 2017
[cited by applicant]
Kawahara et al. Engineering cytokine receptors to control cellular functions (Biochem Eng J. Feb. 15, 2010;48(3):283-294).
[cited by examiner]
Single-domain antibody—Wikipedia, pp. 1-11; down loaded Aug. 22, 2024.
[cited by examiner]
Di Stasi et al., “T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model”, Blood, 2009; 113 (25): 6392-6402.
[cited by applicant]
Co-pending U.S. Appl. No. 15/801,133, filed Nov. 1, 2017.
[cited by applicant]
Abate-Daga, et a.; “CAR models: next-generation CAR modifications for enhanced T-cell function”; Molecular Therapy-Oncolytics; vol. 3, 7 pages (2016).
[cited by applicant]
Baitsch, et al.; “Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization”; PLoS One; vol. 7, No. 2, 10 pages (Feb. 2012).
[cited by applicant]
Barnea, et al.; “The genetic design of signaling cascades to record receptor activation”; PNAS; vol. 105, No. 1, pp. 64-69 (Jan. 8, 2008).
[cited by applicant]
Chaudhry et al., “Energetics of glutamate receptor ligand binding domain dimer assembly are modulated by allosteric ions”, PNAS, 2009, 106(30): 12329-12334.
[cited by applicant]
Chen et al., “Overexpression of a glutamate receptor (GluR2) ligand binding domain in
[cited by applicant]
Co-pending U.S. Appl. No. 15/835,329, filed Dec. 7, 2017.
[cited by applicant]
Camacho-Soto, et al.; “Ligand-Gated Split-Kinases”; Journal of the American Chemical Society; vol. 136, pp. 3995-4002 (2014).
[cited by applicant]
Camacho-Soto, et al.; “Small Molecule Gated Split-Tyrosine Phosphatases and Orthogonal Split-Tyrosine Kinases”; Journal of the American Chemical Society; vol. 136, No. 49, 9 pages (2014).
[cited by applicant]
Cartellieri, et al.; “Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer”; J. Biomed. Biotechnol.; vol. 2010, 13 pages (2010).
[cited by applicant]
Chelur, et al.; “Targeted cell killing by reconstituted caspases”; PNAS; vol. 105, No. 2, pp. 2283-2288 (Feb. 13, 2007).
[cited by applicant]
Curran, et al.; “Chimeric Antigen Receptors for T cell Immunotherapy: Current Understanding and Future Direction”; J. Gene. Med.; vol. 14, No. 6, pp. 405-445 (Jun. 2012).
[cited by applicant]
Dasgupta, et al.; “Nuclear Receptor Coactivators: Master Regulators of Human Health and Disease”; Annu. Rev. Med.; vol. 65, pp. 279-292 (2014).
[cited by applicant]
Davila, et al.; “How do CARs work?: Early insights from recent clinical studies targeting CD19”; Oncoimmunology; vol. 1, No. 9, pp. 1577-1583 (Dec. 1, 2012).
[cited by applicant]
Derose, et al.; “Manipulating signaling at will: chemically-inducible dimerization (CID) techniques resolve problems in cell biology”; Pflugers Arch; vol. 465, No. 3, pp. 409-417 (Jan. 9, 2013).
[cited by applicant]
Di Stasi, et al.; “Inducible apoptosis as a safety switch for adoptive cell therapy”; N Engl J Med; vol. 365, No. 18, pp. 1673-1683 (Nov. 3, 2011).
[cited by applicant]
Dotti, et al.; “Design and development of therapies using chimeric antigen receptor-expressing T cells”; Immunological Reviews; vol. 257, pp. 107-126 (2014).
[cited by applicant]
Duttagupta, et al.; “Costimulation Signals for Memory CD8+T Cells During Viral Infections”; Crit. Rev. Immunol.; vol. 29, No. 6, pp. 469-486 (2009).
[cited by applicant]
Fegan, et al.; “Chemically controlled protein assembly: techniques and applications”; Chem Rev; vol. 110, No., 6, pp. 3315-3336 (Jun. 9, 2010).
[cited by applicant]
Fridy, et al.; “A robust pipeline for rapid production of versatile nanobody repertoires”; Nat. Methods; vol. 11, No. 12, pp. 1253-1260 (Dec. 2014).
[cited by applicant]
Fridy, et al.; “A robust pipeline for rapid production of versatile nanobody repertoires”; Nat. Methods; vol. 11, No. 12, pp. 1253-1260 (Dec. 2014)—Supplemental Materials.
[cited by applicant]
Garfall, et al.; “Immunotherapy with Chimeric Antigen Receptors for Multiple Myeloma”; Discovery Medicine; vol. 17, No. 91, pp. 37-46 (Jan. 2014).
[cited by applicant]
Gizinski, et al.; “Costimulation and T cells as therapeutic targets”; Best Pract. Res. Clin. Rheumatol.; vol. 24, No. 4, pp. 463-477 (Aug. 2010).
[cited by applicant]
Gooz; “ADAM-17: The Enzyme That Does It All”; Crit. Rev. Biochem. Mol. Biol.; vol. 45, No. 2, pp. 146-169, 146-169 (Apr. 2010).
[cited by applicant]
Gordon, et al.; “Effects of S1 cleavage on the structure, surface export, and signaling activity of human Notch1 and Notch2”; PLoS One; vol. 4, No. 8, 12 pages (Aug. 2009).
[cited by applicant]
Graef, et al.; “Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70”; EMBO J; vol. 16, No. 18, pp. 5618-5628 (Sep. 15, 1997).
[cited by applicant]
Gurevich, et al.; “Corepressors of agonist-bound nuclear receptors”; Toxicology and Applied Pharmacology; vol. 223, pp. 288-298 (2007).
[cited by applicant]
Heldin, et al.; “Dimerization of Cell Surface Receptors in Signal Transduction”; Cell; vol. 80, pp. 213-223 (Jan. 27, 1995).
[cited by applicant]
Hultman, et al.; “The Ligand-Dependent Interaction of Mineralocorticoid Receptor with Coactivator and Corepressor Peptides Suggests Multiple Activation Mechanisms”; Molecular Endocrinology; vol. 19, No. 6, pp. 1460-1473…
[cited by applicant]
Isakov; “Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades”; J. Leukoc . Biol.; vol. 61, No. 1, pp. 6-16 (Jan. 1997).
[cited by applicant]
James, et al.; “Biophysical mechanism of T-cell receptor triggering in a reconstituted system”; Nature; vol. 487, pp. 64-69 (Jul. 5, 2012).
[cited by applicant]
Juillerat, et al.; “Design of chimeric antigen receptors with integrated controllable transient functions”; Scientific Reports; doi: 10.1038/srep18950; 7 pages (Jan. 11, 2016).
[cited by applicant]
Kalos, et al.; “T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia”; Sci Transl Med.; vol. 3, No. 95, 12 pages (Aug. 10, 2011).
[cited by applicant]
Kawahara, et al.; “Engineering cytokine receptors to control cellular functions”; Biochemical Engineering Journal; vol. 48, pp. 283-294 (2010).
[cited by applicant]
Kimchi-Sarfaty, et al.; “A ‘Silent’ Polymorphism in the MDR1 Gene Changes Substrate Specificity”; Science; vol. 315, pp. 525-528 (Jan. 26, 2007).
[cited by applicant]
Klemm et al., “Dimerization as a Regulatory Mechanism in Signal Transduction”, Annu. Rev. Immunol., 1998, 16: 569-592.
[cited by applicant]
Kloss, et al.; “Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells”; Nat Biotechnol; vol. 31, pp. 71-75 (Dec. 16, 2012).
[cited by applicant]
Kopan, et al.; “The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism”; Cell; vol. 137, pp. 216-233 (Apr. 17, 2009).
[cited by applicant]
Lanitis et al., “Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor”, Molecular Therapy, Mar. 2012, 20(3): 633-643.
[cited by applicant]
Lecourtois, et al.; “Indirect evidence for Delta-dependent intracellular processing of notch in
[cited by applicant]
Lemmon et al., “Cell signaling by receptor-tyrosine kinases”, Cell, 2010, 141(7): 1117-1134.
[cited by applicant]
Li et al., “Receptor tyrosine kinase transmembrane domains”, Cell Adhesion & Migration, 2010, 4:2, 249-254.
[cited by applicant]
Liu, et al.; “Construction of a fluorescein-responsive chimeric receptor with strict ligand dependency”; Biotechnol Bioeng. Dec. 1, 2008;101(5):975-84. doi: 10.1002/bit.21961.
[cited by applicant]
Maus, et al.; “Antibody-modified T cells: CARs take the front seat for hematologic malignancies”; Blood; vol. 123, No. 17, pp. 2625-2635 (Apr. 24, 2014).
[cited by applicant]
Matsuda, et al.; “Synthetic Signal Propagation Through Direct Cell-Cell Interaction”; Sci. Signal; vol. 5, No. 220, 9 pages (Apr. 17, 2012).
[cited by applicant]
Maus et al., “Antibody-modified T cells: CARs take the front seat for hematologic malignancies”, Blood, Apr. 24, 2014, 123(17): 2625-2635.
[cited by applicant]
Mumm, et al.; “A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1”; Mol. Cell; vol. 5, No. 2, pp. 197-206 (Feb. 2000).
[cited by applicant]
Nagy, et al.; “Mechanism of the nuclear receptor molecular switch”; Trends in Biochemical Sciences; vol. 29, No. 6, pp. 317-324 (Jun. 2004).
[cited by applicant]
Ngo, et al.; “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”; The Protein Folding Problem and Tertiary Structure Prediction; pp. 433 and 492-495 (1994).
[cited by applicant]
Odorizzi, et al.; “Inhibitory Receptors on Lymphocytes: Insights from Infections”; J. Immunol.; vol. 188, No. 7, pp. 2957-2965 (Apr. 1, 2012).
[cited by applicant]
Ogawa, et al.; “Construction of Unnatural Heterodimeric Receptors Based on IL-2 and IL-6 Receptor Subunits”; Biotechnol. Prog.; vol. 29, No. 6, pp. 1512-1518 (2013).
[cited by applicant]
Olefsky, et al.; “Minireview Prologue: Nuclear Receptor Minireview Series”; J. Biol. Chem.; vol. 276, pp. 36863- 36864 (2001).
[cited by applicant]
Ott et al., “Integral membrane protein biosynthesis: why topology is hard to predict”, Journal of Cell Science, 2002, 115: 2003-2009.
[cited by applicant]
Porter, et al.; “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia”; Engl J Med; vol. 365, No. 8, pp. 725-733 (Aug. 25, 2011).
[cited by applicant]
Raulet; “Roles of the NKG2D Immunoreceptor and Its Ligands”; Nature Reviews Immunology; vol. 3, pp. 781-790 (Oct. 2003).
[cited by applicant]
Robyr, et al.; “Nuclear Hormone Receptor Coregulators in Action: Diversity for Shared Tasks”; Molecular Endocrinology; vol. 14, No. 3, pp. 329-347 (2000).
[cited by applicant]
Rosenberg; “Raising the bar: the curative potential of human cancer immunotherapy”; Science Translational Medicine; vol. 4, Issue 127, pp. 127ps8 (Mar. 23, 2012).
[cited by applicant]
Sadelain, et al.; “The Basic Principles of Chimeric Antigen Receptor Design”; Cancer Discovery; vol. 3, No. 4, pp. 388-398 (Apr. 2013).
[cited by applicant]
Sadelain, et al.; “The promise and potential pitfalls of chimeric antigen receptors”; Current Opinion in Immunology; vol. 21, No. 2, pp. 215-223 (Apr. 1, 2009).
[cited by applicant]
Sanchez-Irizarry, et al.; “Notch Subunit Heterodimerization and Prevention of Ligand-Independent Proteolytic Activation Depend, Respectively, on a Novel Domain and the LNR Repeats”; Molecular and Cellular Biology; vol. …
[cited by applicant]
Schreiber; “Chemical Genetics Resulting from a Passion for Synthetic Organic Chemistry”; Bioorganic & Medicinal Chemistry; vol. 6, pp. 1127-1152 (1998).
[cited by applicant]
Song, et al.; “In vivo persistence, tumor localization and anti-tumor activity of CAR engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)”; Cancer Res.; vol. 71, No. 13, pp. 4617-4627 (Jul. 1…
[cited by applicant]
Spencer et al., “Controlling Signal Transduction with Synthetic Ligands”, Science, Nov. 12, 1993, 262: 1019-1024.
[cited by applicant]
Springael et al., “Dimerization of chemokine receptors and its functional consequences”, Cytokine & Growth Factor Reviews, 2005, 16: 611-623.
[cited by applicant]
Stashi, et al.; “Steroid Receptor Coactivators: Servants and Masters for Control of Systems Metabolism”; Trends Endocrinol. Metab.; vol. 25, No. 7, pp. 337-347 (Jul. 2014).
[cited by applicant]
Stroud et al., “Mechanistic Diversity of Cytokine Receptor Signaling Across Cell Membranes”, Science's STKE., 2004: re7.
[cited by applicant]
Struhl, et al.; “Nuclear access and action of notch in vivo”; Cell; vol. 93, No. 4, pp. 649-660 (May 15, 1998).
[cited by applicant]
Stuhlmann-Laeisz, et al.; “Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells”; Mol Biol Cell. Jul. 2006; 17(7):2986…
[cited by applicant]
Tal, et al.; “An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities”; Oncotarget; vol. 5, No. 21, pp. 10949-10958 (Apr. 24, 2014).
[cited by applicant]
Tetel; “Nuclear receptor coactivators: Essential players in steroid hormone action in brain and behavior”; J. Neuroendocrinol; vol. 21, No. 4, pp. 229-237 (Mar. 2009).
[cited by applicant]
Tone, et al.; “Cell Fate Conversion by Conditionally Switching the Signal-Transducing Domain of Signalobodies”; Biotechnology and Bioengineering; vol. 110, No. 12, pp. 3219-3226 (Dec. 2013).
[cited by applicant]
Voet, et al.; Biochemistry; pp. 126-128 (1990).
[cited by applicant]
Vooijs, et al.; “Mapping the consequence of Notch1 proteolysis in vivo with NIP-CRE”; Development; vol. 132, No. 3, pp. 535-544 (Feb. 2007).
[cited by applicant]
Wang et al., “Structural Biology of Shared Cytokine Receptors”, Annu Rev Immunol., 2009, 27: 29-60.
[cited by applicant]
Weissman, et al.; “Molecular cloning and chromosomal localization of the human T-cell receptor zeta chain: distinction from the molecular CD3 complex”; PNAS; vol. 85, No. 24, pp. 9709-9713 (Dec. 1988).
[cited by applicant]
Wu, et al.; “Remote control of therapeutic T cells through a small molecule-gated chimeric receptor”; Sciencexpress; sciencemag.org/content/early/recent; doi: 10.1126/science.aab4077; 15 pages (Sep. 24, 2015).
[cited by applicant]
Yang et al., “Activation of Growth Hormone Receptors by Growth Hormone and Growth Hormone Antagonist Dimers: Insights into Receptor Triggering”, Molecular Endocrinology, 2008, 22(4): 978-988.
[cited by applicant]
Zhang et al., “LAT: The ZAP-70 Tyrosine Kinase Substrate that Links T Cell Receptor to Cellular Activation”, Cell, Jan. 9, 1998, 92: 83-92.
[cited by applicant]
Zhao, et al.; “Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor”; Cancer Res.; vol. 70, No. 22, pp. 9053-9061 (Nov. 15, 2010).
[cited by applicant]
Bayle et al., “Rapamycin Analogs with Differential Binding Specificity Permit Orthogonal Control of Protein Activity”, Chemistry & Biology, 2006, 13: 99-107.
[cited by applicant]
Borras et al., “Generic Approach for the Generation of Stable Humanized Single-chain Fv Fragments from Rabbit Monoclonal Antibodies”, The Journal of Biological Chemistry, 2010, 285(12): 9054-9066.
[cited by applicant]
Chowdhury et al., “Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity”, Proc. Natl…
[cited by applicant]
Ex Parte Luara S. Grosmaire et al., Decision on Appeal issued for U.S. Appl. No. 11/493,132, mailing date: Oct. 12, 2018.
[cited by applicant]
Ho et al., “A novel high affinity human monoclonal antibody to mesothelin”, Int J Cancer., 2011, 128(9): 2020-2030.
[cited by applicant]
Kang et al., “Targeted Coating With Antigenic Peptide Renders Tumor Cells Susceptible to CD8+ T Cell-mediated Killing”, Molecular Therapy, 2013, 21(3): 542-553.
[cited by applicant]
Ma et al., “Recognition of Mesothelin by the Therapeutic Antibody MORAb-009”, The Journal of Biological Chemistry, 2012, 287(40): 33123-33131.
[cited by applicant]
Wei et al., “Target selection for CAR-T therapy”, Journal of Hematology & Oncology, 2019, 12:62, 9 pages.
[cited by applicant]